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Aims: To evaluate the visual and fluorescein angiographic outcomes of photodynamic therapy (PDT) with
verteporfin in patients with subfoveal choroidal neovascularisation (CNV) caused by pathologic myopia in
the Chinese.
Methods: Prospective, non-comparative, two centre interventional study. Patients with CNV secondary to
pathologic myopia of Chinese ethnicity were recruited and treated with a standard regimen of PDT with
verteporfin. Results of this study in Chinese eyes with pigmented retinal pigment epithelium were compared
with those from the Verteporfin in Photodynamic Therapy (VIP) Study of predominantly white eyes.
Results: Thirty one and 22 eyes that completed the 12 month and 24 month follow up studies respectively
were analysed. The mean and median best corrected visual acuities (BCVA) could be maintained at the
baseline level at the 12 month and 24 month visits. Fourteen (63.6%) eyes had stable or improved BCVA
at 24 months and six (27.3%) of them had a moderate gain in vision (improved by three or more lines).
Visual results were comparable with that of the VIP study, but the average accumulative PDT treatments
required in one and two years were 1.7 and 2.3 respectively, which were significantly less than 3.4 and
5.1 treatments in VIP study. Mean logMAR BCVA of the younger age group (,55 years) at 24 months
was 0.41 (SD 0.29), which was significantly better than the older age group (>=55 years) of 0.82 (SD
0.40) (Mann-Whitney U test, p = 0.029).
Conclusions: PDT using the predetermined treatment protocol has achieved similar visual outcomes in the
Chinese population as in white people with subfoveal myopic CNV over a 2 year study period. The
complete cessation of CNV leakage can be accomplished, on average, with fewer PDT retreatments than
reported in the VIP study. The disparity may be due to ethnic differences in these two populations.
P
athologic myopia is more common in Asian adult
population and the prevalence is around 9%1 which is
much higher than that of 2% in the United States.2 High
myopia is the seventh leading cause of legal blindness in
adult Americans3 and ranks second in the blind registration
of Hong Kong where the majority of the population is
Chinese.4 Retinal and macular abnormalities including
choroidal neovascularisation (CNV), chorioretinal atrophy,
and retinal detachment are some of the ocular complications
in patients with high myopia of excessive axial length.5 The
estimated risk in developing CNV from pathologic myopia is
about 4–10%6–8 and the natural course of subfoveal CNV is
somewhat controversial but generally regarded as poor.7 9–12
In a series of Asian patients with myopic subfoveal CNV, the
best corrected visual acuity (BCVA) dropped by 2.0 lines in a
3 year follow up, 5.0 lines in 5 years, and 5.7 lines in
10 years.13 Avila et al observed 70 eyes with untreated CNV
from a predominantly white population with an average
follow up of 41 months; 51% have stable or improved visual
acuity.9
Different modalities of treatment, including direct laser
photocoagulation and submacular surgery, have been pro-
posed in the management of subfoveal CNV secondary to
pathologic myopia but the outcomes were not encouraging.14–16
The one year results of the Verteporfin in Photodynamic
Therapy (VIP) trial demonstrated that verteporfin treated
patients had a higher chance of stabilising or improving
vision in patients with subfoveal CNV secondary to
pathologic myopia.17
There is a wide diversity in prevalence of fundus diseases
between Asian and white eyes.19–22 The different degrees of
pigmentation in the retinal pigment epithelial layers of
dissimilar races may also affect the optimal treatment
parameters and outcomes of treatments through diverse
mechanisms.23–26 In the VIP study, 91% of patients were white
and only 4% Asian.17 Whether Asian or Chinese eyes with
pigmented retinal pigment epithelium layers respond differ-
ently to the standard verteporfin infusion protocol and
predetermined laser energy level is not known. This
prospective study investigated the treatment outcomes of
PDT on myopic subfoveal CNV in the Chinese population over
one and two year periods.
SUBJECTS AND METHODS
This was a prospective, consecutive, interventional study
involving two centres aimed at investigating the safety and
efficacy of PDT with verteporfin for subfoveal CNV of
pathologic myopia in the Chinese population. Subfoveal is
defined as the involvement of the centre of the foveolar
avascular zone.17 The protocol was reviewed and approved by
the ethics committee of the Chinese University of Hong Kong
and consent was obtained from each patient.
Patient selection
Patients were recruited from two tertiary ophthalmic centres
in Hong Kong: Hong Kong Eye Hospital and Prince of Wales
Hospital, and enrolment started in February 2000.
Abbreviations: BCVA, best corrected visual acuity; CNV, choroidal
neovascularisation; FA, fluorescein angiography; PDT, photodynamic




Inclusion criteria of the study included: (1) pathologic
myopia defining as high myopia with spherical equivalent
(26.0 dioptres or axial length >26.5 mm; (2) aged 18 years
or older; (3) CNV at the subfoveal area; (4) greatest linear
dimension of the entire lesion not exceeding 5400 mm; (5)
BCVA of at least 20/200 or better, and (6) active CNV in
clinical and in angiography.
Exclusion criteria included: (1) other clinical features
suggesting that the CNV may be secondary to causes other
than pathologic myopia (such as large drusen, geographical
atrophy, choroioretinal scar); (2) any systemic contraindica-
tions for verteporfin or angiographic dyes; (3) patients who
had received previous treatment before enrolment; (4)
significant concurrent ocular or macular diseases.
Pretreatment assessment and photodynamic therapy
All participants received a comprehensive ocular examination
including dilated fundus and macular examinations with a
contact lens or a 90 diopter lens, followed by colour fundus
photography, fluorescein angiography (FA) at baseline and
then every 3 months. BCVA was measured by certified
optometrist with a standard Snellen chart. In order to
quantify differences in vision, all Snellen BCVA have been
converted to the logarithm of the minimum angle of
resolution (logMAR) BCVA.27 Photodynamic therapy was
given with the standard verteporfin (Visudyne, Novartis AG,
Bu¨lach, Switzerland) infusion followed by laser application at
689 nm (Coherent Inc, CA, USA).17
Follow up, retreatment, and end point
Patients were seen every 3 months and retreatment was
considered if there was persistent or new leakage in FA.
Retreatment was given in the same manner as the initial
treatment described. Treatment end point was deemed
achieved when there was complete absence of angiographic
leakage in FA. In equivocal cases, a biomicroscropic contact
lens examination together with optical coherence tomogra-
phy in delineating the morphology of fibrotic CNV and
absence of subretinal or intraretinal fluid were helpful.
Outcome measurements
Primary outcomes were proportion of eyes that had improved
(one or more lines), stable, or decreased (one or more lines)
vision at the end of the first and second years. Mean and
median changes in visual acuities at months 12 and 24 were
measured.
Secondary outcome parameters included number of treat-
ments required, the associated factors for better outcomes,
and proportion of eyes with final vision loss of three or more
lines. Any ocular or systemic adverse events caused by PDT
were also tabulated.
Statistical analysis
Demographic characteristics of patients including the angio-
graphic findings were summarised by descriptive statistics
using statistical software (SPSS version 10.1.0, SPSS Inc,
Chicago, IL, USA). Comparisons between initial and final
visual acuities and among different groups were performed
by Wilcoxon signed ranks test and Mann-Whitney U test
respectively. Potential risk factors such as age and degree of
myopia were analysed by Pearson correlation.
RESULTS
Characteristics of patients
From February 2000 to September 2003, 31 eyes from 30
patients with subfoveal CNV secondary to pathologic myopia
had completed 1 year’s follow up and of them, 22 eyes from
21 patients had completed 2 years’ follow up. There were 20
(66.7%) females and 10 (33.3%) males; all were southern
Chinese. Seventeen patients involved the left eye whereas 12
involved the right and one had bilateral involvement. Mean
(standard deviation (SD)) of age at presentation was 51.6
(SD 14.8) years, range 31–82 years. Refractive error ranged
from 26.00 D to 222.00 D and mean (SD) was 210.65 (SD
4.13) D.
Visual outcomes at 1 year of follow up (31 eyes)
On initial presentation, the mean logMAR BCVA was 0.61
(SD 0.32). The initial Snellen BCVA ranged from 20/25 to 20/
200 with a mean of 20/81. The median Snellen BCVA on
presentation was 20/100 (logMAR 0.70). At 1 year of follow
up, the mean logMAR BCVA was 0.57 (SD 0.36). The Snellen
BCVA ranged from 20/20 to 20/200 with a mean of 20/74. The
median Snellen BCVA was 20/70 (logMAR 0.54).
Thirteen (41.9%) eyes had BCVA improved by one or more
lines and eight (25.8%) of these eyes had a moderate gain in
vision (three or more lines). Twelve (38.7%) eyes had stable
vision and six (19.4%) eyes had visual loss of one line or more.
The mean and median lines of improvement were 0.7 and 1.6
lines respectively, but the change in the mean logMAR BCVA
at 12 months was not statistically significant (Wilcoxon signed
ranks test, p=0.145). The changes in BCVA of each individual
case at 12 months are displayed in the scatter diagram (fig 1).
At baseline, nine (29.0%) patients had initial BCVA of 20/40 or
better. At the 12 month follow up, 12 (38.7%) patients had
BCVA of 20/40 or better. This, however, was not statistically
significant (McNemar test, p=0.508).
Visual outcomes at 2 years’ follow up (22 eyes)
For those eyes that completed the 2 years’ follow up, initial
mean logMAR BCVA was 0.59 (SD 0.34). At 2 years’ follow
up, the mean logMAR BCVA was 0.56 (SD 0.38). There was
also no statistically significant change in the mean BCVA
(Wilcoxon signed ranks test, p=0.500). The initial and the
final median logMAR BCVA were 0.70 and 0.47 respectively.
Most of the visual improvement occurred within the first
3 months after the initial PDT, but the visual gain was
gradually lost and the vision returned back to the baseline
level in subsequent follow ups (fig 2).
Eight (36.4%) eyes had final BCVA improved by one or
more lines and in which six (27.3%) of these eyes had a
moderate gain in vision (three or more lines). Eight (36.4%)
eyes had visual loss of one line or more and remaining six
Figure 1 Scatter plot showing the change in visual acuities at one and
two year visits with photodynamic therapy
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(27.3%) eyes had stable vision. Changes in BCVA of each
individual case at 24 months are displayed in the scatter
diagram (fig 1).
Number of PDT sessions
A total of 54 treatment sessions had been given to 31 eyes in
the first year with a mean of 1.7 treatments. Eighteen
(58.0%) eyes received only one single PDT session during the
12 month study period. Retreatment was performed for cases
with persistent, recurrent or new angiographic leakage in FA.
Four (12.9%) eyes required two PDT sessions, eight (25.8%)
eyes required three, and one (3.2%) eye required four
sessions of PDT.
In the second year, most of the eyes remained stable
angiographically. One had persistent CNV that required an
additional three more sessions in the second year. Four had
recurrent CNV in the second year, in which two received one
more and the other two received two more sessions. On
average, the cumulative treatment sessions needed for the 22
study eyes over the 2 year follow up period was 2.3 (figs 3
and 4).
Risk factor analysis
Age is not related to the preoperative VA (r=0.321,
p=0.079). However, the younger the patient, the better the
VA at 12 months (r=0.594, p,0.001) and 24 months
(r=0.501, p=0.018) after PDT. In addition, younger patients
also have better improvement in visual acuity at 12 months
(r=0.386, p=0.032) and 24 months (r=0.445, p=0.038)
postoperatively.
In further analysis with different age groups (,55 and
>55 years), the mean logMAR VA for patients,55 years was
0.36 (SD 0.28) and that for patients >55 years was 0.82 (SD
0.32) (Mann-Whitney U test, p=0.001). The mean logMAR
VA at 24 months also showed that patients in the younger
age group (,55 years) (0.41 (SD 0.29)) were significantly
better than patients in the older age group (>55 years)
(0.82 (SD 0.40)) (Mann-Whitney U test, p=0.029). The
median logMAR VA at 12 months for patients ,55 years and
>55 years were 0.30 and 1.00 respectively; the median
logMAR VA at 24 months for patients ,55 years and
>55 years were also 0.30 and 1.00 respectively.
Concerning different degrees of refractive errors (>212 D
or ,212 D), there is no statistically significant difference in
the logMAR VA at 12 months (Mann-Whitney U test,
p=0.716) and at 24 months (Mann-Whitney U test,
p=0.541).
Adverse events and complications
Four developed haemorrhagic complications during the study
period. All resolved gradually with time. Transient visual
disturbance was reported in five eyes. Potential but serious
complications such as severe acute loss of vision, and rip or
tear in RPE did not occur in our series. None of the patients
suffered from any discomfort or complications arising from
infusion or laser application such as low back pain, catheter
induced complications, photosensitivity, and so on.
DISCUSSION
Choroidal neovascularisation in the subfoveal area can cause
significant loss of vision by affecting the RPE and neurosen-
sory retina.7 8 Pathologic myopia is a common underlying
disease in causing CNV. Compared with age related macular
degeneration, it affects a younger age group and the loss of
vision can be severe and may not be recovered with any
further treatment.
Hotchkiss et al reported a series of 23 eyes in 23 patients
with CNV associated with high myopia.7 Deterioration of
visual acuity was shown in 51% of eyes, with a final visual
acuity of 20/200 or less in 44% of eyes.7 Avila et al reported a
series of 70 eyes in 58 patients with untreated CNV associated
with high myopia in which 60% had the final vision of 20/200
or less.9 From the placebo arm of the VIP study, which was
the only prospective series in the literatures, 17 out of 39 eyes
(43%) had stable or improved vision at both 1 year and 2 year
follow up.17 18
The data gathered so far from submacular surgery for
subfoveal CNV of pathologic myopia are less promising, as
the visual results are frequently unpredictable and severe
early loss of vision is possible.15 16 Macular translocation
surgery may also be considered as a treatment option for
subfoveal CNV associated with pathologic myopia.28
However, the surgical techniques are demanding and
complications are not uncommon.29 Similar to submacular
surgery, there has to date been no randomised study
demonstrating its long term efficacy.
Some beneficial outcomes have been shown in verteporfin
treated group of VIP study.17 Primary outcome, however, was
no longer statistically significant in the second year follow up
study.18 That may be caused by the loss of efficacy of PDT or
subtle adverse effects of the treatment on neurosensory
retina and RPE in long run.
In our study, the vision was preserved at the end of the
follow up. No significant functional changes of the mean and
median visual acuities at months 12 and 24 from the baseline
level were found. The overall visual outcomes are comparable
with the VIP study. Indeed, more eyes (63.6%, 14 of 22 eyes)
achieved stable or improved vision in the present series at the
completed second year of follow up in comparison with the
control group (44%, 17 of 30 eyes) of the VIP study.
Age is a determinant affecting the outcomes of myopic
CNV. Yoshida et al showed that the younger ((40 years)
generally have a better prognosis. About half the patients
retained a final visual acuity better than 20/40 and there was
no significant change in mean VA with a follow up period of
3 years or more. Those findings might be accounted for by
the smaller size of CNV, and less chorioretinal atrophy in the
younger age group. As suggested by the author, the age at the
time of onset of myopic CNV should be considered in
deciding any intervention.30 In the risk factors analyses of our
study, it has been shown that younger patients (,55 years)
with myopic subfoveal CNV responded better to PDT than the
older age group (>55 years) at both 12 months and
24 months (Mann-Whitney U test, p=0.001 and p=0.029
respectively).31
The present study adopted the same angiographic endpoint
as in the VIP study. The average number of treatments
achieving complete absence of leakage in the first year and
the accumulated number in the second year was 1.7 and 2.3,
which were much lower than 3.4 and 5.1 treatment sessions
Figure 2 Changes in the mean logMAR BCVA with time over the
24 month follow up
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in the VIP study respectively. The pigmented RPE may
provide a more protective effect from the unrestrained
growth of the CNV after PDT, or there might be some other
confounding factors accounting for the disparity in the
average number of PDT treatments. Concerning complica-
tions or side effects from the therapy, there are no new safety
concerns with the same treatment protocol and laser energy.
Our series, however, has its own limitations including a
small sample size, a short follow up period, and no
comparative control group. This study design does not allow
us to conclude the efficacy of PDT in the Asian population to
treat subfoveal CNV from myopic degeneration as there was
no control observation arm. The number of retreatments
required in achieving stable angiographic results is less in our
series. Whether or not the Asian population, which has more
fundus pigmentation, responds differently from non-Chinese
patients may warrant a comparative trial with controls.
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Figure 3 Left eye of a 56 year old
Chinese woman with myopia of 28.00
diopters (D) manifesting as choroidal
neovascularisation (CNV). The baseline
best corrected visual acuity (BCVA) was
20/200. (A) Fundus photography
showing CNV of 1 disc diameter at
subfoveal region together with a rim of
subretinal haemorrhage. (B, C) Early
phase fluorescein angiography (FA)
showing a well delineated classic
membrane with early
hyperfluorescence and profuse
angiographic leakage in the late phase.
(D) Fundus photography at 3 months
after photodynamic therapy (PDT)
showing a CNV of the same size. The
adjacent haemorrhage was partially
reabsorbed. (E, F) Early and late phase
of FA showing a CNV with mild
angiographic leakage with time as
shown by increasing
hyperfluorescence, an ill defined
border, and increasing in size of
hyperfluorescence in late phase
compared with early phase.
Retreatment with PDT was required in
accordance with angiographic
manifestations. (G) The CNV becoming
a fibrotic scar and associated with
atrophy of adjacent retinal pigment
epithelium. (H, I) No vasacular leakage
was revealed in subsequent follow ups
and the early and late phase of the FA
at 2 years showed a non-leaking scar.
The BCVA remained at 20/200.
Figure 4 Right eye of a 44 year old
Chinese man with myopia of
211.00 D. (A) Fundus photograph
revealing a small subfoveal lesion with
subretinal haemorrhage. The baseline
best corrected visual acuity (BCVA) was
20/100. (B) Early phase fluorescein
angiography (FA) showing a tiny well
defined choroidal neovascularisation
(CNV). (C) Late phase FA showing
profuse angiographic leakages from
the CNV. (D) Fundus photograph at
3 months after PDT, revealing a small
contracting lesion together with a rim of
hyperplastic retinal pigment epithelium.
(E) Early phase FA showing a
circumscribed lesion with
hyperfluorescence. (F) Late phase FA
showing same level and same
dimension of hyperfluorescence. The
edge of the lesion remained sharp and
clear and it was compatible with scar
staining. No repeated PDT was offered
and the angiographic morphology
remained the same in the subsequent
follow ups together with a stable BCVA
at the level of 20/70 at the 2 year visit.
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